Literature DB >> 17031296

Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series.

Parveen Sen1, Lingam Gopal, Pratik Ranjan Sen.   

Abstract

PURPOSE: To report the efficacy of intravitreal voriconazole.
METHODS: Retrospective analysis of an interventional case series of five cases of culture-proven fungal endophthalmitis treated with intravitreal voriconazole was done. Only cases found to be resistant to conventional antifungal agents were included in the study. The diagnosis of fungal endophthalmitis was established on the basis of clinical as well as microbiological examination. All patients received one or more intravitreal injections of voriconazole. Resolution was determined on the basis of clinical examination. Resolution of infection and final visual acuity were the main outcome measures.
RESULTS: Resolution of infection was achieved in all five cases. Visual acuity was better in three cases and was maintained in two. Of the three patients who had improvement, two had vision better than or equal to 20/120. Evisceration was avoided in one case with maximal antifungal treatment including voriconazole.
CONCLUSIONS: Voriconazole definitely adds to the available treatment options for fungal endophthalmitis. Because of its broad spectrum of activity, it is efficacious in even amphotericin-B- and fluconazole-resistant fungal endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031296     DOI: 10.1097/01.iae.0000250011.68532.a2

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

1.  Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole.

Authors:  Andrea Zarkovic; Stephen Guest
Journal:  Int Ophthalmol       Date:  2007-09-28       Impact factor: 2.031

2.  Cytotoxicity of voriconazole on cultured human corneal endothelial cells.

Authors:  Sang Beom Han; Young Joo Shin; Joon Young Hyon; Won Ryang Wee
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

3.  Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis.

Authors:  Jorge Vila Arteaga; Mayerling Mercedes Suriano; Oana Stirbu
Journal:  Int Ophthalmol       Date:  2011-07-17       Impact factor: 2.031

Review 4.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

5.  Pharmacokinetics and safety of intravitreal caspofungin.

Authors:  Ying-Cheng Shen; Chiao-Ying Liang; Chun-Yuan Wang; Keng-Hung Lin; Min-Yen Hsu; Hon-Leung Yuen; Li-Chen Wei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

7.  Successful salvage therapy of Fusarium endophthalmitis secondary to keratitis: an interventional case series.

Authors:  Grant M Comer; Maxwell S Stem; Stephen J Saxe
Journal:  Clin Ophthalmol       Date:  2012-05-09

8.  Successful management of presumed Candida endogenous endophthalmitis with oral voriconazole.

Authors:  Raju Biju; Daniel Sushil; Nainan K Georgy
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

9.  Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis.

Authors:  Hijab Mehta; Hitendra B Mehta; Prashant Garg; Harish Kodial
Journal:  Indian J Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.848

Review 10.  Cladosporium keratitis - a case report and literature review.

Authors:  Steve Chih-Hsuan Cheng; Ying-Yu Lin; Chien-Neng Kuo; Li-Ju Lai
Journal:  BMC Ophthalmol       Date:  2015-08-19       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.